• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.

作者信息

Zheng N, Guo C, Wu R

机构信息

a Department of Rheumatology and Immunology , The First Affiliated Hospital of Nanchang University , Nanchang , PR China.

出版信息

Scand J Rheumatol. 2018 Sep;47(5):422-424. doi: 10.1080/03009742.2017.1376109. Epub 2018 Jan 10.

DOI:10.1080/03009742.2017.1376109
PMID:29318937
Abstract
摘要

相似文献

1
Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.艾拉莫德对甲氨蝶呤-环孢素A-羟氯喹-泼尼松治疗反应不佳的难治性类风湿关节炎患者有效。
Scand J Rheumatol. 2018 Sep;47(5):422-424. doi: 10.1080/03009742.2017.1376109. Epub 2018 Jan 10.
2
Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis.患者摘要。在甲氨蝶呤治疗早期类风湿关节炎时加用小剂量泼尼松。
Ann Intern Med. 2012 Mar 6;156(5):I18. doi: 10.7326/0003-4819-156-5-201203060-00001.
3
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.艾拉莫德联合甲氨蝶呤治疗活动性类风湿关节炎：疗效观察
Z Rheumatol. 2016 Oct;75(8):828-833. doi: 10.1007/s00393-015-1641-y.
4
Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.一名类风湿关节炎患者在甲氨蝶呤和依那西普治疗基础上加用艾拉莫德14周后发生了耶氏肺孢子菌肺炎。
Mod Rheumatol. 2018 Nov;28(6):1041-1043. doi: 10.1080/14397595.2016.1181026. Epub 2016 May 16.
5
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.小剂量泼尼松加入甲氨蝶呤为基础的紧密控制策略治疗早期类风湿关节炎：一项随机试验。
Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.
6
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.
Rheum Dis Clin North Am. 1998 Aug;24(3):465-77. doi: 10.1016/s0889-857x(05)70020-x.
7
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.在甲氨蝶呤稳定剂量治疗下仍处于活动期的类风湿关节炎患者中联合使用来氟米特治疗：一项随机、双盲、安慰剂对照试验。
Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26.
8
Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.环孢素联合英夫利昔单抗和甲氨蝶呤用于难治性类风湿关节炎。
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):916-7.
9
Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum.甲氨蝶呤联合依那西普治疗类风湿关节炎的临床疗效及其对血清 HOTAIR 表达水平的影响。
Biomed Res Int. 2021 Nov 12;2021:2486617. doi: 10.1155/2021/2486617. eCollection 2021.
10
[Combination therapy in rheumatoid arthritis].[类风湿关节炎的联合治疗]
Tidsskr Nor Laegeforen. 2003 May 29;123(11):1511-3.

引用本文的文献

1
Decreased Expression of IL-35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia.IL-35 及其受体表达降低导致免疫性血小板减少症发病机制中的巨核细胞生成受损。
Adv Sci (Weinh). 2024 Mar;11(12):e2305798. doi: 10.1002/advs.202305798. Epub 2024 Jan 15.
2
[Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis].托法替布联合艾拉莫德治疗难治性中重度类风湿关节炎的疗效
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Dec 18;55(6):1013-1021. doi: 10.19723/j.issn.1671-167X.2023.06.009.
3
Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer.
艾拉莫德作为系统性硬化症的替代疗法及预防缺血性指端溃疡的发生。
Front Med (Lausanne). 2023 May 5;10:1113408. doi: 10.3389/fmed.2023.1113408. eCollection 2023.
4
Effect of combined application of iguratimod in the treatment of active rheumatoid arthritis on bone metabolism, Th17 cells and Treg cells.艾拉莫德联合应用治疗活动期类风湿关节炎对骨代谢、辅助性T细胞17及调节性T细胞的影响
Am J Transl Res. 2021 Mar 15;13(3):1676-1684. eCollection 2021.
5
Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.勘误：艾拉莫德作为类风湿关节炎的新药：现状
Front Pharmacol. 2020 Apr 8;11:488. doi: 10.3389/fphar.2020.00488. eCollection 2020.
6
Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.艾拉莫德作为类风湿关节炎的新药：现状
Front Pharmacol. 2020 Feb 26;11:73. doi: 10.3389/fphar.2020.00073. eCollection 2020.
7
Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.依古比托治疗剂量依赖性抑制类风湿关节炎患者中性粒细胞中瓜氨酸化蛋白和肽基精氨酸脱亚氨酶 2 和 4 的表达。
Clin Rheumatol. 2020 Mar;39(3):899-907. doi: 10.1007/s10067-019-04835-4. Epub 2019 Nov 22.
8
Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis.依古比托治疗能够抑制与 PKC/EGR1 轴抑制相关的 B 细胞终末分化。
Arthritis Res Ther. 2019 Apr 11;21(1):92. doi: 10.1186/s13075-019-1874-2.